Palvella Therapeutics, Inc. (PVLA)

Every figure this model derived for PVLA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-09-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 171,000 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 250,584,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 253,028,000 AssetsCurrent 2026-06-30
current liabilities 11,947,000 LiabilitiesCurrent 2026-06-30
equity 216,867,000 StockholdersEquity 2026-06-30
revenue 1,352,000 Revenues 2024-09-30
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PVLA on one particular measure came for.

RatioValue
current ratio21.18
current ratio reported21.18
deferred revenue growth-100.0
growth cv2.43
revenue growth-97.15
revenue growth per share-97.15
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about PVLA's figures. Written by the derivation as it ran, not added afterwards.